Association between ischaemic heart disease and interstitial lung disease: A case–control study  by Ponnuswamy, A. et al.
Respiratory Medicine (2009) 103, 503e507ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedAssociation between ischaemic heart disease and
interstitial lung disease: A caseecontrol studyA. Ponnuswamy, R. Manikandan, A. Sabetpour, I.M. Keeping, J.P. Finnerty*Countess of Chester Hospital, Liverpool Road, Chester CH2 1UL, UK
Received 22 June 2008; accepted 5 January 2009
Available online 3 February 2009KEYWORDS
Interstitial lung disease;
Pulmonary fibrosis;
Coronary artery disease* Corresponding author. Tel.: þ44
363756.
E-mail addresses: aravindpdr@ya
rajamani.manikandan@coch.nhs.uk
sabetpour@coch.nhs.uk (A. Sabetpo
com ( I .M. Keep ing ) , finner ty@
(J.P. Finnerty).
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.01.004Summary
Background: Idiopathic pulmonary fibrosis (IPF) is increasing in incidence. One of the authors
noted that many of his patients with IPF were taking statins, and suspected an association.
A caseecontrol study was undertaken to investigate the association of statins with interstitial
lung disease.
Methods: The study population comprised patients attending the respiratory outpatients diag-
nosed with IPF between the beginning of 1999 and the beginning of July 2004, and 50 cases
were identified. Data regarding the age, sex, smoking habits, occupational histories, exposure
to birds, co-morbidity (ischaemic heart disease, diabetes, atrial fibrillation, and hyperlipidae-
mia), biopsy evidence for IPF, and use of beta blockers, statins, aspirin, NSAIDS, loop diuretics
and proton pump inhibitors were recorded. Two age and sex-matched controls were obtained
for each case from patients attending a general gastroenterology clinic within 3 months of
attendance of the case, and thus 100 controls were obtained. Data on the controls were
collected as for the cases.
Results: Of the cases, 12 of 50 were taking statins compared with 20 of 100 controls (matched
OR 1.13, CI 0.30e4.24, NS). Coronary artery disease was seen in 20 of 50 cases and 20 of 100
controls (matched OR 5.37, CI 1.52e19.0, p< 0.01).
Conclusions: There was no statistically significant association between the use of statins and
the diagnosis of interstitial lung disease. However there was a statistically significant associa-
tion between ischaemic heart disease and the diagnosis of ILD.
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Interstitial lung disease (ILD) has more than doubled in
incidence in the UK over recent years.1 It is therefore
reasonable to question why this should be, and to explore
any association between changes in drug prescribing over
recent years and the development of IPF. Previous experi-
ence has shown that newly introduced drug therapy can be.
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even years after exposure.2 One possibility which we
considered was the now widespread prescription of statins:
one of the authors (I.M.K.) noted that many of his patients
with IPF were taking statins, and suspected an association
between the increasing incidence of IPF and the increasing
use of statins in the general population. In support of this
theory was the observation that the World Health Organi-
sation UMC has reported at least 59 cases of pulmonary
fibrosis associated with various brands of statins.3 Seem-
ingly in conflict with our hypothesis, statins have also been
considered to have a potential therapeutic effect in IPF in
view of their anti-inflammatory properties demonstrated in
other chronic inflammatory conditions. We undertook
a caseecontrol study to investigate any association
between statins and the development of IPF.
Methods
Selection of cases
We searched for cases of IPF diagnosed whilst attending our
respiratory outpatient clinics from clinical coding on the
basis of international classification of diseases code for
interstitial lung fibrosis and from lists of clinic letters with
a name search for interstitial fibrosis or interstitial pneu-
monitis on the Medisec system. Cases were also collated
from a list of patients who had undergone high resolution
CT scan for the diagnosis. Care was taken to include only
patients from 1999 to July 2004 as statins were available
over the counter since this date. In total, 50 cases of IPF
were identified in this way and included in the study. The
index attendance was the date of the clinical attendance at
which the diagnosis of IPF was made.
All the cases were patients diagnosed by experienced
respiratory physicians (I.M.K. and J.P.F.), both practising
over the period of the diagnoses (1999e2004). In all of the
cases, the case-notes were obtained, and we confirmed that
a clinical diagnosis of IPF (whether UIP or NSIP) was made.
Given that all of these cases had been followed for several
years, perusal of subsequent correspondence ensured that
no subsequent change in diagnosis had been made. We
excluded cases where any clinical suspicion remained, after
investigation, of sarcoidosis, asbestosis and other fibrotic
lung disease. Interstitial lung disease known to be related to
drug therapy was also excluded from the study population.
All the cases had had HRCT of the lungs, and all of these had
been reviewed at our local X-ray meeting by a radiologist
with a special interest in lung disease.
Care was taken to ensure that these cases were idio-
pathic. We excluded cases where any clinical suspicion
remained, after investigation, of sarcoidosis, asbestosis and
other fibrotic lung disease. Interstitial lung disease known
to be related to drug therapy was also excluded from the
study population.
Selection of controls
For each case, two controls were selected from patients
who had attended a general medical gastroenterology clinic
within 3 months of the index attendance of the case. It wasjudged that there was no a priori reason why such controls
would differ in respect of the use of the prescription drugs
which we were investigating, nor in the background inci-
dence of co-morbidities such as ischaemic heart disease or
hyperlipidaemia, from the general patient group attending
hospital outpatients, and thus we expected a close match
in these characteristics with the cases. Controls were
matched both for age (within five years of the corre-
sponding case) and sex, since both these variables have an
important influence on the incidence of co-morbidities and
consequent drug therapy. The controls were selected in
such a way that they were seen in clinics within 3 months of
the cases being reviewed in the respiratory clinic.
Data collection
Hospital records including admission and inpatient stay
clinic letters; GP letters for outpatient referral and inpa-
tient were reviewed. Drug histories obtained by the clinic
doctor at the index clinical attendance (at which the
diagnosis of IPF was made for the cases or the matched
clinical attendance for the controls) and all correspon-
dence up to three years prior to the date of diagnosis in all
participants of the study population were examined. Data
were collected on an Excel spreadsheet and included
hospital number, age, sex, smoking habit, occupational
history, exposure to birds, and co-morbid conditions
(specifically, ischaemic heart disease, atrial fibrillation,
diabetes mellitus and hyperlipidaemia), and histological
confirmation of IPF if available. A diagnosis of ischaemic
heart disease (IHD) was entered if mentioned in the referral
letter, or if documented to be taking specific anti-anginal
therapy. A diagnosis of smoking was based on the referral
letter, the written clerking in clinic, and the clinic letter.
Lists of all drugs that the patient has taken for up to three
years preceding the date of attendance to the hospital
were photocopied from the notes and entered by the third
investigator, who was blinded to the study objectives.
Similarly data regarding the 100 controls were collected
and lists of drugs were separately listed by a blinded
investigator from lists photocopied from patient notes.
Statistical analysis
The following were analysed as potential risk factors for
IPF: statins, ACE inhibitors, beta blockers, aspirin, proton-
pump inhibitors, non-steroidal anti-inflammatory drugs,
a history of smoking tobacco, diabetes mellitus, atrial
fibrillation, and a history of ischaemic heart disease.
Conditional regression analysis, initially incorporating all
potential risk factors, and subsequently with forward
stepwise dropping of factors with least statistical signifi-
cance, to maximise the likelihood ratio, was performed
using Statsdirect statistical software version 2.6.6. An
analysis of data stratified by smoking history using pooled
data was performed using SPSS v.13.
Results
Our study included 50 cases and 100 age and sex-matched
controls. Of the 50 cases, the age range was 49e89 years
Table 2 Stratified conditional logistic regression with 1:2
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Four patients had a histologically proven UIP and two others
histologically proven NSIP. Twenty cases had received oral
steroids. For the controls, the age range was 51e93 years,
with amean of 72 years, and amale to female ratio of 60e40.
The initial analysis used conditional regression analysis,
with stratification of each case and its two controls: the use
of this stratification makes full statistical use of the
matching, and allows independent analysis of the effect of
the factors on the outcome. All factors were initially
selected and then dropped in the order of the smallest z
factor (except for statins which were kept in the model) to
maximise the fit of the model based on the McFadden
R-square value. The results are shown in Table 1.
Using this analysis, the presence of IHD and the use of
ACE inhibitors are associated with increased odds of having
ILD. A weak effect of beta blockers is observed, significant
at the 5% level, such that the administration of beta
blockers is associated with reduced odds of having ILD.
Reviewing this data, it was suggested that in general
practice, interstitial lung disease may have been initially
diagnosed as congestive cardiac failure (CCF), given the
presence of basal inspiratory crackles in both disease
states, and the fact that CCF is a considerably commoner
condition. This could account for the apparent negative
association with the use of beta blockers (since at the time,
beta blockade was not common practice in the treatment
of CCF). In general practice, ACE inhibitors are prescribed
in both hypertension and CCF, but loop diuretics are almost
exclusively prescribed for CCF. We therefore went back to
our data and looked out prescriptions of loop diuretics. Five
of the controls and thirteen of the cases were taking loop
diuretics at the initial consultation with us, or had had
them prescribed in the previous three years. The condi-
tional logistic regression analysis was therefore repeated,
including loop diuretics as one of the factors, and iterating
as above. The model obtained is presented in Table 2.
Thus, once loop diuretic use was used as a factor, the
apparent association between ACE inhibitor use and ILDTable 1 Stratified conditional logistic regression with 1:2
caseecontrol matching, with ILD as the dependent variable,
and the following conditions/prescriptions as independent
variables: diabetes, IHD, ACE inhibitor, beta blocker, statin,
aspirin, non-steroidal anti-inflammatory drugs, and current
smoking.
Factor Odds ratio 95% CI for odds ratio p Value
Diabetes 0.78 0.13e4.48 0.77
ACE-Inhibitor 3.60 1.17e11.0 0.025*
IHD 4.26 1.52e11.88 0.006*
Beta-blocker 0.24 0.06e0.89 0.032*
Statin 0.98 0.32e2.99 0.97
Aspirin 0.57 0.17e1.91 0.36
NSAID’s 1.16 0.23e5.83 0.86
Current smoker 0.53 0.15e1.91 0.33
Likelihood ratio
Chi square
McFadden R square p Value
22.08 0.204 0.0048
*Significant at 5% level.reduced, and did not reach statistical significance. The
apparent protective effect of beta blockers was no longer
statistically significant at the 5% level. The association
between IHD and ILD remained statistically significant
(p< 0.01).
Further analysis was performed using the same factors
as in the last analysis, but looking for interactions between
ischaemic heart disease and use of the following: loop
diuretics, beta blockers, current smoking and ACE inhibi-
tors. This weakened the fit of the model (p value fell to
0.0017), and none of the interactions approached statistical
significance (for interaction with loop diuretics, pZ 0.30,
for beta blockers, pZ 0.77, for smoking pZ 0.87, and for
ACE inhibitors pZ 0.50).
A further analysis of the data was performed, stratifying
by smoking history (current, ex-smokers, and never
smokers), using the pooled data (i.e. not stratified by cases
and controls). The results are shown in Table 3.
The ManteleHaenszel Common Odds Ratio estimate for
IHD in patients with ILD compared with controls is 2.747
(95% confidence intervals 1.27e5.93). Tarone’s test for
homogeneity of the odds ratio gives Chi-square value of
1.486, df 2, pZ 0.476, so there is no evidence that the odds
ratios differ between the 3 strata. The ManteleHaenszel
test for conditional independence gives Chi square 5.93, df
1, pZ 0.015, indicating a significant association between
ischaemic heart disease and interstitial lung disease, as
previously demonstrated by the conditional regression
analysis above.
Discussion
Our original hypothesis was that the use of statins was
associated with the diagnosis of ILD. Our study showed no
evidence for this, but showed an association between thecaseecontrol matching, with ILD as the dependent variable,
and independent variables as for Table 1 with the addition
of loop diuretic, atrial fibrillation and proton pump inhibitor
as factors.
Factor Odds ratio 95% CI for odds ratio p Value
Loop diuretic 8.73 1.97e38.7 0.0043*
Diabetes 0.62 0.10e4.01 0.62
ACE-inhibitor 3.49 0.92e13.2 0.066
Atrial fibrillation 0.38 0.06e2.56 0.32
IHD 5.37 1.52e19.0 0.009*
Beta-blocker 0.23 0.05e1.03 0.054
Statin 1.13 0.30e4.24 0.85
Aspirin 0.38 0.08e1.67 0.20
NSAID’s 0.90 0.18e5.18 0.91
PPI 0.77 0.28e2.07 0.60
Current smoker 0.53 0.14e2.11 0.37
Likelihood ratio
Chi square
McFadden R square p Value
32.25 0.298 0.0007
*Significant at 5% level.
Table 3 Pooled data on the presence or absence of IHD in
cases and controls, stratified by the smoking history.
Smoking history ILD No ILD Total
Never smoked IHD 8 6 14
No IHD 12 44 56
Ex-smoker IHD 7 7 14
No IHD 15 25 40
Current smoker IHD 5 7 12
No IHD 3 11 14
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of ILD.
Histological diagnosis of ILD was achieved in only 6 of the
50 cases. While we are confident that all the cases had ILD,
this is a heterogeneous condition including at least two
conditions, UIP and NSIP, which have different clinical
courses, and which may be associated differently with
a variety of causative factors. Thus our study may have
under-estimated an association with one or more of these
sub-groups.
There is some evidence in the literature of pulmonary
pathology arising from the use of statins. For example,
there are case reports of statins leading to lupus-like
syndromes,4,5 polymyositis/dermatomyositis with lung
involvement,6,7 and hypersensitivity pneumonitis8 associ-
ated with statin therapy. The timing of onset appears
unpredictable, with many patients having been taking statin
therapy for manymonths or years before symptoms develop.
Clinical features have varied in severity from mild dry cough
and rash through to severe and progressive respiratory
failure. Hypersensitivity pneumonitis with granuloma
formation, diffuse alveolar damage and non-specific inter-
stitial pneumonitis has been associated with the use of sta-
tins in various case reports.9 There is considerable
theoretical evidence suggesting that ACE inhibition may
conversely have a protective or preventative effect on the
development of fibrosis in cardiac cells10 and renal mesan-
gial cells.11 However, Nardous et al. showed that there was
no survival advantage with statin.12 The data from the
current study provide no evidence for any benefit or harm
from the use of statins in ILD. The confidence intervals for
the odds ratios are wide, and one cannot conclude from this
data that there is no clinically important risk (or conversely,
benefit) from the use of statins in ILD. The power of the study
is limited by the rarity of the disease, and so the difficulty in
obtaining a large number of cases. We could have obtained
more cases from our recent records, but we could not be
confident in a retrospective study about the use of statins,
given their availability over the counter from July 2004.
One must of course be cautious in a study of this size in
interpreting the sizes of the effects demonstrated, since
the confidence intervals are wide. However, the effects
shown are clearly at a statistically significant level for IHD,
and the raw data suggest that the association is strong.
Previous caseecontrol studies have identified smoking13
and diabetes14 as risk factors for the development of idio-
pathic pulmonary fibrosis, particularly in association with
environmental exposures. No association was noted in the
current study.Our initial results showed an association between the
prescription of ACE inhibitors, the diagnosis of ischaemic
heart disease, and ILD. The diagnosis of IHD was recorded to
assess its role as a potential confounding factor in the
prescription of statins and cardiac drugs prescribed. The
strong association between ACE inhibitor use and ILD was
independent of the diagnosis of IHD. However, the weak-
ening of the association when loop diuretics are considered
as a factor, and the strong association between loop diuretic
use (and the avoidance of beta blockers) and ILD strongly
suggests that the cause of the apparent association is due to
initial mis-diagnosis of ILD as congestive cardiac failure.
This does not exclude a relationship between ACE
blockade and ILD. There has been intense research into the
renin angiotensin system and its role in the pathophysiology
of fibrosis. In various models, inhibition of angiotensin
convertase (ACE) has attenuated induced lung fibrosis,
generating interest in ACE inhibition as a potential treat-
ment. Nadrous and colleagues12 looked at survival in
patients with IPF who for clinical reasons were on ACE
inhibitors, but found no survival advantage: in fact,
although no statistically significant differences were found,
the survival curve for IPF patients on ACE inhibitors was
slightly worse than for those who were not taking ACE
inhibitors. ACE exists predominantly in a membrane-bound
form, generated by vascular endothelial cells in the
pulmonary vasculature, but also circulates in plasma. An
elevation of serum ACE levels is well known in sarcoidosis,
but elevations of ACE in bronchoalveolar fluid have been
observed in idiopathic pulmonary fibrosis.15 Angiotensin II
(AII) is generated by the proteolytic cleavage of its
precursor, angiotensin I, by ACE. AII acts via AT1 and AT2
receptors. AT1 receptors have been implicated in the
proliferation of fibroblasts16 whereas activation of AT2
receptors has been shown to inhibit cell growth.17 A recent
study showed that in lung tissue from patients undergoing
transplantation for IPF, the expression of both AT1 and AT2
was increased in comparison with control specimens, with
a relatively greater increase in AT2 expression.18 Using an
animal model, the same investigators demonstrated the
same findings in bleomycin-induced lung fibrosis, and found
that treatment of fibroblasts derived from this source with
AII decreased proliferation, an effect abrogated by AT2
receptor blockade. It is at least plausible, if one accepts
this data of differing actions of AII depending on whether
the source material is healthy or from lung fibrosis, that
blockade of the generation of AII could be deleterious in
the presence of pulmonary fibrosis.
Our study showed a strong association between the
diagnosis of coronary artery disease and ILD. This was not
explained by any difference in the frequency of diabetes,
hyperlipidaemia, or smoking history. Similarly, it could not
be explained by differences in the use of statins, ACE
inhibitors, beta blockers or loop diuretics. There was no
evidence of any interaction between the diagnosis of
ischaemic heart disease and the use of loop diuretics, beta
blockers or ACE inhibitors. Thus there appears to be an
association between the diagnosis of ischaemic heart
disease and interstitial lung disease that is independent of
the drugs prescribed for the patients. These results are
consistent with the findings of Rizer et al.,19 who conducted
a cross-sectional study of patients referred for lung
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artery disease in patients with fibrotic versus non-fibrotic
lung disease. They found an increased prevalence of IHD in
patients with fibrotic lung disease, with an Odds Ratio of
2.18 after correction for traditional risk factors for IHD. Our
study independently confirms this observation, using
a control group without lung disease. One possible expla-
nation is that one process promotes the other: that
atherosclerosis prompts fibrosis, or pulmonary fibrosis
prompts atherosclerosis. For example, macrophages from
atherosclerotic plaques show an enhanced capacity to
produce IL-8 compared with normal and are a major site of
IL-8 mRNA production in atherosclerotic plaques.20 Tissue
specimens from patients from IPF show levels of IL-8
significantly greater than in control specimens.21
In conclusion, our caseecontrol study does not support
our original hypothesis of an association between statins
and ILD. There is an association between loop diuretic use
and the diagnosis of ILD which we interpret as likely to be
due to mis-diagnosis of ILD as CCF. An association between
IHD and ILD was demonstrated, which persists when we
account for the use of cardiac drugs. There may be an
interaction between the inflammatory processes in both
diseases. Clinicians should be aware of the significantly
increased risk of coronary artery disease in patients pre-
senting with ILD.
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